1|0|Public
40|$|The {{feasibility}} of collecting {{detailed information on}} the marketing authorization of new medicines in the European Union was investigated by conducting a study to ob-tain data {{on the use of}} the <b>concertation</b> <b>procedure.</b> Ten pharmaceutical companies provided information on 13 biotechnology or high technology products going through the procedure between 1988 and 1993. The main reason fo r choosing the rapporteur state was for its experience. Discussions with the rapporteur were consid-ered useful, particularly for guidance, facilitating timely responses to questions and forestalling divergence of opinion. The total length of time of the procedure ranged from 272 - 882 days. The length of time to national marketing authorization following a favorable Committee for Proprietary Medicinal Products (CPMP) opinion ranged from 5 - 1. 374 days. The rapporteur authority tended overall to be the quickest, and conversely, authorities dissenting in the original CPMP opinion were among the slowest to grant national authorization. In general, good harmonization of the sum-mary of product characteristics was achieved. This study provides companies with useful in formation on the <b>concertation</b> <b>procedure</b> and will also be helpful for design-ing future studies of the newly established centralized and mutual recognition proce-dures...|$|E

